Evidence map›Paper›PMID 31036503›Full record

Observational studyThe lancet. Diabetes & endocrinology2019

Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study.

Qiuhong Gong, Ping Zhang, Jinping Wang, Jixiang Ma, Yali An, Yanyan Chen, Bo Zhang, Xinxing Feng, Hui Li, Xiaoping Chen and 6 more

2 registry-linked trialsAbstract readObservational Study
In one paragraph

Observational study in The lancet. Diabetes & endocrinology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 341 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
341citing papers in PubMed, 9 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06958640 enrolling by invitationnot on this mapstarted 2025, after this paper: background citation

Da Qing Offspring Study

TypeobservationalSponsorChina-Japan Friendship HospitalRan2025 to 2026Enrolled5,000ConditionsDiabetes Mellitus, Cardiovascular Diseases (CVD), Offspring, Adult, Impaired Glucose Tolerance (Prediabetes)ArmsLifestyle interventions
NCT07654062 phase4not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Efficacy and Safety of Mazdutide in Adults With Prediabetes: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial (DREAM-PRE)

TypeinterventionalSponsorShandong Provincial HospitalRan2026 to 2029Enrolled150ConditionsPrediabetes, Impaired Fasting Glucose, Impaired Glucose Tolerance (Prediabetes)ArmsMazdutide, Placebo, Standardized Lifestyle Intervention
3 · Its place in the literature

Who cites it

341 citing papers in PubMed, 9 syntheses or guidelines pooled it.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Guideline
  8. Pooled it
  9. Pooled it
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Rosiglitazone improves insulin resistance but does not improve exercise capacity in individuals with impaired glucose tolerance: A randomized clinical study.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2024
    Trial

281 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Qiuhong GongEndocrinology and Cardiovascular Disease Centre, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Ping ZhangDivision of Diabetes Translation, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Jinping WangDepartment of Cardiology, Da Qing First Hospital, Da Qing, China.
Jixiang MaDivision of Non-Communicable Disease Control and Community Health, Chinese Center for Disease Control and Prevention, Beijing, China.
Yali AnEndocrinology and Cardiovascular Disease Centre, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Yanyan ChenEndocrinology and Cardiovascular Disease Centre, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Bo ZhangChina-Japan Friendship Hospital, Beijing, China.
Xinxing FengEndocrinology and Cardiovascular Disease Centre, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China.
Hui LiDepartment of Cardiology, Da Qing First Hospital, Da Qing, China.
Xiaoping ChenChina-Japan Friendship Hospital, Beijing, China.
Yiling J ChengDivision of Diabetes Translation, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Edward W GreggDivision of Diabetes Translation, US Centers for Disease Control and Prevention, Atlanta, GA, USA.
Yinghua HuDepartment of Cardiology, Da Qing First Hospital, Da Qing, China.
Peter H BennettPhoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, AZ, USA.
Guangwei LiEndocrinology and Cardiovascular Disease Centre, Fuwai Hospital, Chinese Academy of Medical Sciences, Beijing, China; China-Japan Friendship Hospital, Beijing, China. Electronic address: guangwei_li45@126.com.
Da Qing Diabetes Prevention Study Group

Funding

ACL HHS U19GH000636CGH CDC HHS U19 GH000636Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundLifestyle interventions can delay the onset of type 2 diabetes in people with impaired glucose tolerance, but whether this leads subsequently to fewer complications or to increased longevity is uncertain. We aimed to assess the long-term effects of lifestyle interventions in people with impaired glucose tolerance on the incidence of diabetes, its complications, and mortality.

methodsThe original study was a cluster randomised trial, started in 1986, in which 33 clinics in Da Qing, China, were randomly assigned to either be a control clinic or provide one of three interventions (diet, exercise, or diet plus exercise) for 6 years for 577 adults with impaired glucose tolerance who usually receive their medical care from the clinics. Subsequently, participants were followed for up to 30 years to assess the effects of intervention on the incidence of diabetes, cardiovascular disease events, composite microvascular complications, cardiovascular disease death, all-cause mortality, and life expectancy.

findingsOf the 577 participants, 438 were assigned to an intervention group and 138 to the control group (one refused baseline examination). After 30 years of follow-up, 540 (94%) of 576 participants were assessed for outcomes (135 in the control group, 405 in the intervention group). During the 30-year follow-up, compared with control, the combined intervention group had a median delay in diabetes onset of 3·96 years (95% CI 1·25 to 6·67; p=0·0042), fewer cardiovascular disease events (hazard ratio 0·74, 95% CI 0·59-0·92; p=0·0060), a lower incidence of microvascular complications (0·65, 0·45-0·95; p=0·025), fewer cardiovascular disease deaths (0·67, 0·48-0·94; p=0·022), fewer all-cause deaths (0·74, 0·61-0·89; p=0·0015), and an average increase in life expectancy of 1·44 years (95% CI 0·20-2·68; p=0·023).

interpretationLifestyle intervention in people with impaired glucose tolerance delayed the onset of type 2 diabetes and reduced the incidence of cardiovascular events, microvascular complications, and cardiovascular and all-cause mortality, and increased life expectancy. These findings provide strong justification to continue to implement and expand the use of such interventions to curb the global epidemic of type 2 diabetes and its consequences.

fundingUS Centers for Disease Control and Prevention, WHO, Chinese Center for Disease Control and Prevention, World Bank, Ministry of Public Health of the People's Republic of China, Da Qing First Hospital, China-Japan Friendship Hospital, and National Center for Cardiovascular Diseases & Fuwai Hospital.

Indexed as

AdultAgedCardiovascular DiseasesChinaDiabetes Mellitus, Type 2FemaleFollow-Up StudiesGlucose IntoleranceHumansIncidenceLife ExpectancyMaleMiddle AgedRisk Reduction Behavior

Identifiers

PMID31036503
PMCPMC8172050

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.